Inter-individual differences in the metabolism of environmental toxicants:: cytochrome P450 1A2 as a prototype

被引:53
作者
Guengerich, FP
Parikh, A
Turesky, RJ
Josephy, PD
机构
[1] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA
[3] Nestec Ltd, Nestle Res Ctr, CH-1000 Lausanne, Switzerland
[4] Univ Guelph, Dept Chem & Biochem, Guelph Waterloo Ctr Grad Work Chem, Guelph, ON N1G 2W1, Canada
关键词
cytochrome P450; 1A2; human; dinitropyrene; Escherichia coli; expression of proteins in; genetoxicity assay; mutagenesis; random; heterocyclic amine;
D O I
10.1016/S1383-5742(99)00039-3
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Cytochrome P450 (P450) 1A2 provides an interesting paradigm for inter-individual differences in the metabolism of pro-carcinogens. The enzyme is known to vary 40-fold among individuals and may contribute to cancers caused by heterocyclic amines and other chemicals. Rat and human P450 1A2 are known to be 75% identical and were compared for several catalytic activities. The human enzyme was an order of magnitude more efficient in the N-hydroxylation of two heterocyclic amines. Further, the levels of P450 1A2 expressed in human livers show a 40-fold variation, with some as high as 0.25 nmol P450 1A2 per milligram microsomal protein. Some human liver samples are more active (than those isolated from polychlorinated biphenyl-treated rats) in the activation of heterocyclic amines, A bacterial genotoxicity assay has been developed in which human P450 1A2 and NADPH-P450 reductase are expressed within Escherichia coli and bacterial mutants can be assayed using reversion to lac prototrophy. A random mutagenesis strategy for human P450 1A2 has been developed and used to examine the changes in catalytic activity seen with many single-amino acid substitutions. These results may be of relevance in consideration of genetic polymorphisms. Further, the findings pose a challenge to molecular epidemiology effort in that results with one substrate do not necessarily predict those for others. Some dinitropyrenes are P450 1A2 substrates but others are not, 6-Nitrochrysene can be activated by human P450 1A2 but the (mono) nitropyrenes examined were not; these were oxidized by P450 3A4 instead. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:115 / 124
页数:10
相关论文
共 45 条
[1]   HUMAN CDNA-EXPRESSED CYTOCHROME-P450 IA2 - MUTAGEN ACTIVATION AND SUBSTRATE-SPECIFICITY [J].
AOYAMA, T ;
GONZALEZ, FJ ;
GELBOIN, HV .
MOLECULAR CARCINOGENESIS, 1989, 2 (04) :192-198
[2]   Mutational properties of the primary aflatoxin B-1-DNA adduct [J].
Bailey, EA ;
Iyer, RS ;
Stone, MP ;
Harris, TM ;
Essigmann, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (04) :1535-1539
[3]   HALOGENATED BIPHENYLS AS AHH INDUCERS - EFFECTS OF DIFFERENT HALOGEN SUBSTITUENTS [J].
BANDIERA, S ;
SAWYER, T ;
CAMPBELL, MA ;
ROBERTSON, L ;
SAFE, S .
LIFE SCIENCES, 1982, 31 (06) :517-525
[4]  
Barnes HJ, 1996, METHOD ENZYMOL, V272, P3, DOI 10.1016/S0076-6879(96)72003-7
[5]   BIPHASIC O-DEETHYLATION OF PHENACETIN AND 7-ETHOXYCOUMARIN BY HUMAN AND RAT-LIVER MICROSOMAL FRACTIONS [J].
BOOBIS, AR ;
KAHN, GC ;
WHYTE, C ;
BRODIE, MJ ;
DAVIES, DS .
BIOCHEMICAL PHARMACOLOGY, 1981, 30 (17) :2451-2456
[6]  
BOOBIS AR, 1982, BRIT J CLIN PHARMACO, V14, pP602
[7]   HUMAN CYTOCHROME P-450PA (P-450IA2), THE PHENACETIN O-DEETHYLASE, IS PRIMARILY RESPONSIBLE FOR THE HEPATIC 3-DEMETHYLATION OF CAFFEINE AND N-OXIDATION OF CARCINOGENIC ARYLAMINES - (AROMATIC-AMINES HETEROCYCLIC AMINES CARCINOGEN METABOLISM) [J].
BUTLER, MA ;
IWASAKI, M ;
GUENGERICH, FP ;
KADLUBAR, FF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (20) :7696-7700
[8]   DETERMINATION OF CYP1A2 AND NAT2 PHENOTYPES IN HUMAN-POPULATIONS BY ANALYSIS OF CAFFEINE URINARY METABOLITES [J].
BUTLER, MA ;
LANG, NP ;
YOUNG, JF ;
CAPORASO, NE ;
VINEIS, P ;
HAYES, RB ;
TEITEL, CH ;
MASSENGILL, JP ;
LAWSEN, MF ;
KADLUBAR, FF .
PHARMACOGENETICS, 1992, 2 (03) :116-127
[9]  
CHAE YH, 1993, CANCER RES, V53, P2028
[10]  
Chae YH, 1999, CANCER RES, V59, P1473